These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 8473293)
1. Inhibition of apolipoprotein E degradation in a post-Golgi compartment by a cysteine protease inhibitor. Ye SQ; Reardon CA; Getz GS J Biol Chem; 1993 Apr; 268(12):8497-502. PubMed ID: 8473293 [TBL] [Abstract][Full Text] [Related]
2. Lysosomal degradation and sorting of apolipoprotein E in macrophages. Deng J; Rudick V; Dory L J Lipid Res; 1995 Oct; 36(10):2129-40. PubMed ID: 8576639 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in vivo by cysteine protease inhibitors. Inoue S; Bar-Nun S; Roitelman J; Simoni RD J Biol Chem; 1991 Jul; 266(20):13311-7. PubMed ID: 1906466 [TBL] [Abstract][Full Text] [Related]
4. A two-site model for ApoB degradation in HepG2 cells. Wu X; Sakata N; Lele KM; Zhou M; Jiang H; Ginsberg HN J Biol Chem; 1997 Apr; 272(17):11575-80. PubMed ID: 9111073 [TBL] [Abstract][Full Text] [Related]
5. Human plasma lipoproteins regulate apolipoprotein E secretion from a post-Golgi compartment. Ye SQ; Olson LM; Reardon CA; Getz GS J Biol Chem; 1992 Oct; 267(30):21961-6. PubMed ID: 1400506 [TBL] [Abstract][Full Text] [Related]
6. Effects of an inhibitor of cathepsin L on bone resorption in thyroparathyroidectomized and ovariectomized rats. Millest AJ; Breen SA; Loveday BE; Clarkson PN; Simpson CA; Waterton JC; Johnstone D Bone; 1997 May; 20(5):465-71. PubMed ID: 9145244 [TBL] [Abstract][Full Text] [Related]
7. In HepG2 cells, translocation, not degradation, determines the fate of the de novo synthesized apolipoprotein B. Bonnardel JA; Davis RA J Biol Chem; 1995 Dec; 270(48):28892-6. PubMed ID: 7499417 [TBL] [Abstract][Full Text] [Related]
8. Blocking intracellular degradation of the erythropoietin and asialoglycoprotein receptors by calpain inhibitors does not result in the same increase in the levels of their membrane and secreted forms. Neumann D; Yuk MH; Lodish HF; Lederkremer GZ Biochem J; 1996 Jan; 313 ( Pt 2)(Pt 2):391-9. PubMed ID: 8573070 [TBL] [Abstract][Full Text] [Related]
10. The production of 85 kDa N-terminal fragment of apolipoprotein B in mutant HepG2 cells generated by targeted modification of apoB gene occurs by ALLN-inhibitable protease cleavage during translocation. Srivastava N; Cefalu AB; Noto D; Schonfeld G; Averna M; Srivastava RA Biochem Biophys Res Commun; 2010 Aug; 398(4):665-70. PubMed ID: 20609357 [TBL] [Abstract][Full Text] [Related]
11. Evidence that a rapidly turning over protein, normally degraded by proteasomes, regulates hsp72 gene transcription in HepG2 cells. Zhou M; Wu X; Ginsberg HN J Biol Chem; 1996 Oct; 271(40):24769-75. PubMed ID: 8798747 [TBL] [Abstract][Full Text] [Related]
12. Effect and cellular site of action of cysteine protease inhibitors on the cholesterol esterification pathway in macrophages and Chinese hamster ovary cells. Schissel SL; Beatini N; Zha X; Maxfield FR; Tabas I Biochemistry; 1995 Aug; 34(33):10463-73. PubMed ID: 7654700 [TBL] [Abstract][Full Text] [Related]
13. Intracellular degradation of type I collagen and fibronectin in human lung fibroblasts: evidence against degradation in pre-lysosomal compartments. Andersson LM; Warburton MJ Biochim Biophys Acta; 1995 Jul; 1268(1):27-34. PubMed ID: 7626659 [TBL] [Abstract][Full Text] [Related]
14. Proteolysis and lipid-facilitated translocation are distinct but competitive processes that regulate secretion of apolipoprotein B in Hep G2 cells. Sakata N; Wu X; Dixon JL; Ginsberg HN J Biol Chem; 1993 Nov; 268(31):22967-70. PubMed ID: 8226809 [TBL] [Abstract][Full Text] [Related]
15. Studies of the sites of intracellular degradation of apolipoprotein B in Hep G2 cells. Furukawa S; Sakata N; Ginsberg HN; Dixon JL J Biol Chem; 1992 Nov; 267(31):22630-8. PubMed ID: 1429611 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of intracellular sorting and processing of lysosomal cathepsins H and L at reduced temperature in primary cultures of rat hepatocytes. Nishimura Y; Kawabata T; Yano S; Kato K Arch Biochem Biophys; 1990 Dec; 283(2):458-63. PubMed ID: 2275557 [TBL] [Abstract][Full Text] [Related]
17. Ubiquitin-proteasome pathway mediates intracellular degradation of apolipoprotein B. Yeung SJ; Chen SH; Chan L Biochemistry; 1996 Oct; 35(43):13843-8. PubMed ID: 8901527 [TBL] [Abstract][Full Text] [Related]
18. Effects of tocotrienol on the intracellular translocation and degradation of apolipoprotein B: possible involvement of a proteasome independent pathway. Wang Q; Theriault A; Gapor A; Adeli K Biochem Biophys Res Commun; 1998 May; 246(3):640-3. PubMed ID: 9618265 [TBL] [Abstract][Full Text] [Related]
19. Intracellular degradation of secretion defect-type mutants of antithrombin is inhibited by proteasomal inhibitors. Tokunaga F; Shirotani H; Hara K; Kozuki D; Omura S; Koide T FEBS Lett; 1997 Jul; 412(1):65-9. PubMed ID: 9257691 [TBL] [Abstract][Full Text] [Related]
20. Degradation of serum albumin by rat liver and kidney lysosomes. Ohshita T; Hiroi Y J Nutr Sci Vitaminol (Tokyo); 1998 Oct; 44(5):641-53. PubMed ID: 9919484 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]